Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration…